Industry News

1 October 2025

Lupin launches Rivaroxaban for oral suspension in the United States

Lupin launches Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States, which is bioequivalent to Xarelto of Janssen Pharmaceuticals, Inc.

1 October 2025

Pfizer to cut prices up to 85% after signing pact with U.S. Government

Pfizer signs pact with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening Americas role as the global leader in biopharmaceutical innovation.

30 September 2025

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR (omalizumab)

Amneal Pharmaceuticals, Inc. announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR

26 September 2025

Alkem launches Pertuza, a pertuzumab biosimilar, in India

Alkem Laboratories Ltd. announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer.

26 September 2025

Glenmark Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), today announced that it has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).

26 September 2025

Lupin Receives Tentative Approval from USFDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets

Global pharma major Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. This product would be manufactured at Lupin’s Nagpur facility in India.

26 September 2025

Unitaid, CHAI, and Wits RHI enter into a landmark agreement with Dr. Reddy’s to make HIV prevention tool lenacapavir affordable in LMICs

The revolutionary HIV prevention tool, injectable lenacapavir, will be available at a cost of USD 40 a year in 120 low- and middle-income countries starting in 2027, under a new partnership announced today between Dr. Reddy’s Laboratories and Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI

20 September 2025

USFDA successfully completes inspection at Indoco’s API manufacturing facility at Patalganga with zero observations

Indoco Remedies Limited announced that the United States Food and Drug Administration successfully completed inspection of its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai. The inspection concluded with zero form 483 observations, reflecting the company's commitment to the highest standards of quality, regulatory compliance and operational excellence.

19 September 2025

Stryker expands its R&D footprint in India with new facility in Bangalore

Stryker a global leader in medical technologies, announced the expansion of its R&D presence in India with the opening of a new facility in Whitefield, Bengaluru. Building on its existing 220,000-square-foot R&D campus in Gurgaon, the new 140,000-square-foot facility further strengthens Stryker’s footprint in the country.

18 September 2025

Dr. Reddys launches novel molecule Tegoprazan in India

Dr. Reddys Laboratories Ltd. announced the launch of the novel molecule Tegoprazan, for acid-related gastrointestinal diseases in India. Dr. Reddys launches Tegoprazan (50 mg) under the brand name PCAB.

Search

Lupin launches Rivaroxaban for oral suspension in the United States

RECOMMENDED POSTS

Subscribe with us

Jobs by Category